Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the month of April 2021, with a specific reporting date of April 12, 2021. The document serves as a transaction notification regarding insider trading activities by Persons Discharging Managerial Responsibilities (PDMRs) and Persons Closely Associated (PCAs) with them.
Key Financial Metrics
The filing does not contain consolidated financial statements, revenue, profit, cash flow, margin, debt, or liquidity metrics. It exclusively reports on specific share acquisition transactions.
| Transaction Date | Instrument | Price per Share | Total Volume | Exchange |
|---|---|---|---|---|
| April 8, 2021 | Ordinary Shares (25p each) | £13.0875 | 2,322 shares | London Stock Exchange (XLON) |
Note: The total volume of 2,322 shares is the aggregate of six individual transactions reported in the filing.
Material Changes
This filing does not report material changes to the company's financial position, operations, or strategy compared to prior periods. It strictly documents routine compliance disclosures for share acquisitions resulting from dividend reinvestment plans.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. The nature of the transactions is identified as the acquisition of ordinary shares following the re-investment of dividends paid to shareholders on April 8, 2021.
Key Facts for Investor Verification
- Transaction Nature: All reported transactions were acquisitions of ordinary shares via dividend reinvestment, not open market purchases or sales.
- Participants: Transactions involved six individuals, including SVPs, the Company Secretary, and their associated persons (PCAs).
- Share Price: The execution price for all transactions was uniform at £13.0875 per share.
- Regulatory Context: This is a mandatory disclosure under Rule 13a-16/15d-16 for a foreign private issuer, not a financial results announcement.